Proton pump inhibitors (PPIs) show up everywhere on the wards—and on Step. They’re “easy points” when you recognize the signature: irreversibly shut down acid secretion at the parietal cell. This post is a quick-hit, shareable PPI comparison with a mnemonic + the high-yield traps USMLE loves.
The 10-second PPI idea (what they do + where they work)
One-liner: PPIs are prodrugs that get activated in the acidic canaliculi of parietal cells and irreversibly inhibit the H⁺/K⁺ ATPase, decreasing gastric acid secretion.
Key consequence: Because inhibition is irreversible, acid secretion returns only after new pumps are synthesized (so the effect lasts longer than the plasma half-life).
Visual / mnemonic device: “The Prazole Parade shuts the Proton Pump Portal”
Picture the parietal cell as a nightclub with a door labeled H⁺/K⁺ ATPase (the “Proton Pump Portal”).
A parade of “-prazoles” marches in and superglues the door shut:
- Ome-prazole
- Esome-prazole
- Lanso-prazole
- Dexlanso-prazole
- Panto-prazole
- Rabe-prazole
Glue = irreversible inhibition → door stays shut until the club installs a new one (new pump synthesis).
PPI comparison table (high-yield, Step-friendly)
Bottom line: For Step exams, most PPIs are clinically similar for acid suppression. Differences matter mainly for CYP interactions and certain exam-style associations.
| Drug | Name clue | Notable Step-relevant “personality trait” | CYP / interactions (high-yield) | Pearl to remember |
|---|---|---|---|---|
| Omeprazole | “Ome” = OG | Classic board example PPI | Inhibits CYP2C19 → can decrease activation of clopidogrel | If a stem mentions clopidogrel + PPI interaction, think omeprazole/esomeprazole |
| Esomeprazole | “Eso” = S-isomer | Similar to omeprazole; common in questions | Also CYP2C19 inhibition (clinically relevant) | “Eso = Enhances interaction risk” (vs other PPIs) |
| Pantoprazole | “Panto” = plays nice | Often favored when you want fewer interactions | Less CYP2C19 inhibition (relative) | If they want a PPI with fewer CYP issues, think pantoprazole |
| Lansoprazole | “Lanso” = standard | Similar efficacy | Typical PPI interaction profile | No special board-only superpower—know class effects |
| Dexlansoprazole | “Dex” = different release | Dual delayed-release formulation (real-life nuance) | Similar to lansoprazole | Rarely tested; treat as “another PPI” unless formulation is highlighted |
| Rabeprazole | “Rabe” = rapid-ish | Similar efficacy; sometimes less CYP dependence emphasized | Typical PPI profile | If a question contrasts “metabolism differences,” rabeprazole may be mentioned |
Class effects you must know (USMLE core)
Mechanism & physiology hooks
- Target: H⁺/K⁺ ATPase on parietal cells
- Effect: ↓ gastric acid → ↑ gastric pH
- Timing pearl: Best taken before meals (so pumps are active and can be inhibited)
Indications (high yield)
- GERD (especially erosive esophagitis)
- Peptic ulcer disease
- H. pylori eradication regimens (combo therapy)
- Zollinger–Ellison syndrome (gastrinoma; very high acid output)
- Stress ulcer prophylaxis in high-risk hospitalized patients (common clinical use)
Adverse effects: the “acid is protective” consequences
Think: removing acid changes absorption, microbes, and bone/minerals.
High-yield adverse effects list
- C. difficile infection risk (less acid barrier → more survival of pathogens)
- Pneumonia (especially early in therapy in some populations; aspiration + altered flora concept)
- Hypomagnesemia
- ↓ Vitamin B12 absorption (acid helps liberate B12 from food proteins)
- ↓ Calcium absorption → fracture risk (association, especially long-term)
- Acute interstitial nephritis (AIN)
- Classic triad vibe: fever, rash, eosinophilia (not always all present)
Board-style association: rebound
- Rebound acid hypersecretion can occur after stopping (upregulated gastrin/ECL signaling).
PPI vs H2 blockers (fast differentiation table)
| Feature | PPIs | H2 blockers |
|---|---|---|
| Block what? | H⁺/K⁺ ATPase | H2 receptor on parietal cell |
| Reversibility | Irreversible | Reversible |
| Potency | Strongest acid suppression | Moderate |
| Time course | Longer effect than half-life | Shorter |
| Classic adverse buzzwords | C. diff, pneumonia, low Mg, B12, fractures, AIN | Cimetidine: gynecomastia, CYP inhibition; confusion in elderly |
| Stress ulcer prophylaxis | Common | Also used, less potent |
Step “gotcha” vignettes (quick patterns)
- Patient on clopidogrel after stent + started a PPI → thrombosis risk concern
→ think omeprazole/esomeprazole inhibit CYP2C19 → ↓ clopidogrel activation. - Long-term PPI + muscle cramps/tremor/arrhythmia
→ suspect hypomagnesemia. - Chronic PPI user + macrocytic anemia/neuropathy
→ consider B12 deficiency. - Hospitalized patient develops profuse watery diarrhea after PPI
→ think C. difficile.
The shareable “PPI one-liner set” (memorize-friendly)
- “PPIs are prodrugs that irreversibly block the proton pump.”
- “Effect outlasts half-life because pumps are knocked out until replaced.”
- “Low acid → infections (C. diff), low Mg, low B12, fractures, AIN.”
- “Omeprazole/esomeprazole can mess with clopidogrel (CYP2C19).”